AGH 2.62 0.00 Vol 0 AGL 30.38 0.00 Vol 0 BAS 1.1 0.00 Vol 0 BFM 18 0.00 Vol 0 BG23B 98.1415 0.00 Vol 0 BPH 5 0.00 Vol 0 DEVON 3.25 0.00 Vol 0 LOM 2.75 -0.02 Vol 10000 NTB 25.25 0.00 Vol 0 ONE 3.9 0.00 Vol 0 POLAR 8.95 0.00 Vol 0 SOM 13.5 0.00 Vol 0 WHHL 0 0.00 Vol 0 WWW 26.5 0.00 Vol 0
Market Closed:

Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020


Hamilton, Bermuda – 22 July 202019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020.  The filing stated:




DUBLIN, July 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2020 financial results and provide a business and financial update.




Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.




Audio webcast/conference call:




U.S. Dial-In Number: +1 855 353 7924


International Dial-In Number: +1 503 343 6056


Passcode: 2644219




A replay of the conference call will be available through August 11, 2020 and accessible through one of the following telephone numbers, using the passcode below:




Replay U.S. Dial-In Number: +1 855 859 2056




Replay International Dial-In Number: +1 404 537 3406


Passcode: 2644219




About Jazz Pharmaceuticals




Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit and follow @JazzPharma on Twitter.




Jazz Pharmaceuticals Contacts:








Kathee Littrell


Vice President, Investor Relations




Ireland, +353 1 634 7887


U.S., +1 650 496 2717








Jacqueline Kirby


Vice President, Corporate Affairs & Government Relations




Ireland, +353 1 697 2141

U.S., +1 215 867 4910


08:30-09:00 Price Discovery
09:00-16:30 Continuous Trading


TEL: +1 (441) 292 7212
FAX: +1 (441) 292 7619


30 Victoria Street
3rd Floor
Hamilton, Bermuda


P.O. Box HM 1369
Hamilton HMFX



The information contained in these pages has been obtained from sources which The Bermuda Stock Exchange believes are reliable. However, the accuracy of the information cannot and is not guaranteed and The Bermuda Stock Exchange makes no representation as to its accuracy or completeness. Neither this Web site, nor any information contained herein, constitutes advice or a solicitation to subscribe, purchase or sell any securities. The Bermuda Stock Exchange expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon any part of the contents of this site or any external sites referenced from this website.